GLP-1 medicines are typically given by injection, and some are available in oral tablet form with specialized absorption technology
The FDA initially approved subcutaneous (SC) use Exenatide in 2005 and an oral version of semaglutide in 2019.2,3 Initially, GLP-1s were used exclusively for individuals with type 2 diabetes (T2DM) as a means to better control their blood sugar when paired with diet and exercise.2 Now their use is growing exponentially due to their success in helping patients achieve significant weight loss
GIP+GLP-1 microneedle patch is a groundbreaking, non-invasive alternative to traditional GLP-1 injections for weight loss , blood sugar control , and type 2 diabetes management
If a patient experiences side effects, the provider may slow down the increase, keep the dose steady longer, or adjust the plan to support comfort and safety
C.CariouB.PiletiM.RoseL.AxelsenM.et al (2017)
Is intestinal microbiota bound up with changing lifestyle